Clinical trials: Allergy to Peanut
Food Allergy, Peanut Allergy
Study to Assess Tolerance of Traces in Peanut/Tree Nut Allergic Children.
This protocol will help better define whether patients with peanut and/or tree nut food allergy can tolerate traces in products with precautionary allergen labelling.
- Conditions
- Food Allergy, Peanut Allergy, Tree Nut Allergy
- Trial name
- NCT03680066
- Testing
- Oral food challenge to foods with traces
- Where
- Switzerland
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- University Hospital, Geneva
Peanut Hypersensitivity
The Effect of Extrinsic Factors on Food Allergy
Food allergy is a common problem, affecting 5-8% of the population. Peanut allergy causes reduced quality of life due to the perceived high risk of severe reactions.
- Trial name
- Ex-Factor (NCT01429896)
- Testing
- Food challenge
- Where
- 2 sites in United Kingdom
- Volunteers
- 100 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Peanut Allergies
Flow CAST® Peanut Trial
This will be a multi-center, prospective evaluation, conducted at a minimum of four (4) U.S. sites. Sites will enroll peanut allergic subjects, subjects with allergies other than peanut and apparently healthy non-atopic control…
- Trial name
- NCT07775430
- Testing
- Basophil activation test
- Volunteers
- 245 people, healthy volunteers welcome
- Sponsor
- Bühlmann Laboratories AG
Allergy, Peanut
Efficacy and Safety of QGE031 (Ligelizumab) in Patients With Peanut Allergy
This was a 52-week, Phase 3 multi-center, randomized, double-blind and placebo-controlled study to assess the safety and clinical efficacy of two dosing regimens of ligelizumab (240 mg and 120 mg) SC q4w (subcutaneous injection…
- Trial name
- NCT04984876
- Testing
- ligelizumab
- Where
- 55 sites in United States, Australia and 8 more
- Volunteers
- 211 people
- Sponsor
- Novartis Pharmaceuticals
Peanut Allergy
Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE)
The purpose of this study is to demonstrate the efficacy and safety of AR101 through reduction in clinical reactivity to peanut allergen in peanut-allergic children and adults.
- Trial name
- PALISADE (NCT02635776)
- Testing
- AR101 powder provided in capsules & sachets
- Where
- 69 sites in United States, Canada and 8 more
- Volunteers
- 555 people
- Sponsor
- Aimmune Therapeutics, Inc.
Tree Nut Allergy
Walnut Oral Immunotherapy for Tree Nut Allergy
The purpose of this study is to determine if walnut oral immunotherapy can be used in participants allergic to tree nuts to reduce tree nut allergy and induce changes in the participant's immune system.
- Trial name
- WOIT (NCT01546753)
- Testing
- Walnut Protein Powder, Open-label Walnut Protein Powder
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Arkansas
Peanut Allergy
Understanding How the Immune System Responds to Viruses in Peanut Allergic Children Undergoing Peanut Oral Immunotherapy
The purpose of this study is to find out if there is a way to treat children with peanut allergy to help lower the risk of severe allergic reactions and also cause them to lose their allergy to peanuts and to understand what…
- Trial name
- DCOIT (NCT01074840)
- Testing
- Peanut flour
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Texas Southwestern Medical Center
Allergy, Nut, Pediatric ALL
Efficiency And Tolerance Of Hazelnut Oral Immunotherapy Protocol In Hazelnut Allergic Children
Prevalence of food allergy in the world has been inscreasing in recent years. Among nut allergy, hazelnut allergy is the most widespread in Europe and particularly in France.
- Trial name
- ENOIME (NCT04841850)
- Testing
- Clinical and biological characteristics
- Where
- France
- Volunteers
- 70 people
- Sponsor
- Hospices Civils de Lyon
Immune Tolerance
Immunologic Profile of Children With Severe Allergies to Peanuts and Nuts After Induction of Tolerance
Many authors propose the strict avoidance of allergenic food as the only treatment for children known to be allergic to certain food.
- Trial name
- TOY (NCT01996774)
- Where
- France
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Lille Catholic University
Peanut Allergy
Treatment of Severe Peanut Allergy With Xolair (Omalizumab) and Oral Immunotherapy
Severe peanut allergy is different from other allergic reactions because it can lead to fatal reactions and is an invisible disability. There is no cure today.
- Trial name
- FASTX (NCT02402231)
- Testing
- Omalizumab
- Where
- Sweden
- Volunteers
- 23 people
- Sponsor
- Caroline Nilsson
Oral Immunotherapy for Food Allergy, Tree Nut Allergy
The NACHO Trial (Nut Allergy Children OIT)
Most food allergies that begin in early childhood are mild and resolve by school age, but nut allergies persist in about 80-90% of individuals into adulthood.
- Conditions
- Oral Immunotherapy for Food Allergy, Tree Nut Allergy, Cashew Nut Allergy
- Trial name
- NCT06930950
- Testing
- Cashew nut oral immunotherapy
- Where
- Finland
- Volunteers
- 45 people
- Sponsor
- HUS Skin and Allergy Hospital
Peanut Allergy
Evaluating the Safety and Efficacy of Oral Encapsulated Fecal Microbiota Transplant in Peanut Allergic Patients
This is a Phase I trial to evaluate the safety and efficacy of oral encapsulated fecal microbiota transplantation (FMT) in the treatment of peanut allergy.
- Trial name
- NCT02960074
- Testing
- Fecal Microbiota Capsule
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Rima Rachid
Food Allergy Peanut, Food Allergy in Infants
Intervention to Reduce Early (Peanut) Allergy in Children
iREACH is a five-year NIH funded study aimed at assessing and improving pediatric clinician adherence to the 2017 NIAID Prevention of Peanut Allergy (PPA) Guidelines.
- Trial name
- iREACH (NCT04604431)
- Testing
- iREACH CDS Tool
- Where
- 30 sites in United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
Food Hypersensitivity
A Study of Sublingual Immunotherapy in Peanut-allergic Children
The specific aim of this study is to determine if peanut allergen-specific SLIT will cause clinical desensitization and tolerance to develop in peanut-allergic young children.
- Trial name
- SLB (NCT00597727)
- Testing
- Peanut SLIT
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of North Carolina, Chapel Hill
Peanut Allergy
Adjuvant Treatment With Abatacept to Promote Remission During Peanut Oral Immunotherapy
This is a phase 2a, multi-center, randomized and double-blind placebo-controlled trial comparing 24 weeks of abatacept versus placebo used as adjuvant to oral immunotherapy to induce remission in adolescents and adults with…
- Trial name
- ATARI (NCT04872218)
- Testing
- Abatacept, Peanut oral immunotherapy
- Where
- Canada
- Volunteers
- 14 people
- Sponsor
- Philippe Bégin
Peanut Allergy, Multi-food Allergy
Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Participants
This study is a multi-center, randomized, double-blind, placebo-controlled study in participants 1 to less than 56 years of age who are allergic to peanut and at least two other foods (including milk, egg, wheat, cashew…
- Trial name
- OUtMATCH (NCT03881696)
- Testing
- Omalizumab, Multi-Allergen Oral Immunotherapy
- Where
- 10 sites in United States
- Volunteers
- 458 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Food Allergies, Peanut Allergies
A Long Term, Observational Follow-Up Study of Children and Young People Who Underwent an 18-Month Course of Oral Immunotherapy Treatment for Peanut, Egg or Milk Allergy (5-15 Years Post-Treatment)
The goal of this observational study is to learn about the long-term outcomes of children and young people who underwent an 18-month course of oral immunotherapy (OIT) treatment for peanut, egg or milk allergy.
- Conditions
- Food Allergies, Peanut Allergies, Egg Allergy, Milk Allergy
- Trial name
- LPEM (NCT07359183)
- Where
- Australia
- Volunteers
- 147 people
- Sponsor
- Murdoch Childrens Research Institute
Allergy
Immunotherapy for Peanut Allergy
Currently, when a food allergy is diagnosed, the "standard of care" is strict avoidance of the allergic food and ready access to self-injectable epinephrine. Yet, accidental ingestions do occur.
- Trial name
- NCT00429429
- Testing
- Sublingual immunotherapy
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of North Carolina, Chapel Hill
Peanut Allergy
Validation of the HYPONUT Product
The HYPONUT product was previously validated in a laboratory setting ("Procédé de préparation d'aliment hypoallergénique", n° FR1250977) on 2012. A international patent was then obtained on 2013.
- Trial name
- NCT03849079
- Testing
- Hyponut
- Where
- France
- Volunteers
- 6 people
- Sponsor
- University Hospital, Montpellier
Food Hypersensitivity, Hypersensitivity
A Randomized, Double-Blind Placebo-Controlled Peanut Sublingual Immunotherapy Trial
The purpose of this study is to evaluate the safety and immune response to daily sublingual (under the tongue) immunotherapy (SLIT) with peanut extract in adults and children with peanut allergies.
- Conditions
- Food Hypersensitivity, Hypersensitivity, Immediate Hypersensitivity, Peanut Hypersensitivity
- Trial name
- NCT00580606
- Testing
- Glycerinated peanut allergenic extract
- Where
- 5 sites in United States
- Volunteers
- 40 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)